-
-
-
-
-
-
-
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma
-
-
-
-
-
-
-
Bristol Myers Squibb’s Application for Breyanzi (lisocabtagene maraleucel) Accepted for Priority Review by U.S. Food and Drug Administration (FDA) in Fifth Cancer Type for Relapsed or Refractory Mar
-
-
-
-
-
-
-
Bristol-Myers Squibb (BMY) Announces FDA Acceptance of Supplemental Biologics License Application for Opdivo Plus Yervoy
-
-
-
-
-
-
-
Morgan Stanley on Zai Lab (ZLAB) Post BMY (BMY) Approval: 'We believe it should bode moderately positively for ZLAB shares'
-
-
-
-
-
-
-
Bristol-Myers Squibb Co. (BMY) PT Lowered to $45 at Deutsche Bank
-
-
-
-
-
-
-
PureTech Announces Annual Results for Year Ended December 31, 2023
-
-
-
-
-
-
-
Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion
-
15,606 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

